Asundexian – Talk Bio

Actionable Insights Powered by AI

Bayer’s Asundexian Fails to Prevent Strokes, Jeopardizing $5.5 Billion Blockbuster Hopes

Bayer, asundexian, stroke prevention, atrial fibrillation, Factor XI inhibitors, clinical trials